Copyright
©The Author(s) 2017.
World J Clin Oncol. Jun 10, 2017; 8(3): 255-260
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.255
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.255
Table 1 Potential biomarkers in the pancreatic juice and bile of patients with pancreatic adenocarcinoma
| Body fluid | Biomarker |
| Pancreatic ductal fluid | CA 19-9 |
| CEA | |
| K-ras | |
| p53 mutations | |
| DNA methylation alterations | |
| Mitochondrial DNA mutations | |
| S100 calcium-binding protein P (S100P) | |
| Human telomerase reverse transcriptase | |
| Matrix metalloproteinase-9 | |
| Oncogene DJ1 | |
| Alpha-1B-glycoprotein precursor | |
| MicroRNA- miR-205, miR-210 | |
| Adnab-9 | |
| S100A8 or A9 | |
| Mucins MUC1, 2, 5AC, 5B, 6 and 13 | |
| Bile | CEA |
| Mac-2-binding protein | |
| MUC4 | |
| Vascular endothelial growth factor |
- Citation: Agrawal S. Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma. World J Clin Oncol 2017; 8(3): 255-260
- URL: https://www.wjgnet.com/2218-4333/full/v8/i3/255.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i3.255